Phase I trial: SABR and ipilimumab - Response

Chad Tang; James W. Welsh; David Hong

doi:10.1158/1078-0432.CCR-16-2621

Phase I trial: SABR and ipilimumab - Response

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	321
Number of pages	1
Journal	Clinical Cancer Research
Volume	23
Issue number	1
DOIs	https://doi.org/10.1158/1078-0432.CCR-16-2621
State	Published - Jan 1 2017

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1158/1078-0432.CCR-16-2621

Cite this

@article{cc26f5069c294a728318b9a902037c8a,

title = "Phase I trial: SABR and ipilimumab - Response",

author = "Chad Tang and Welsh, {James W.} and David Hong",

year = "2017",

month = jan,

day = "1",

doi = "10.1158/1078-0432.CCR-16-2621",

language = "English (US)",

volume = "23",

pages = "321",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "1",

}

TY - JOUR

T1 - Phase I trial

T2 - SABR and ipilimumab - Response

AU - Tang, Chad

AU - Welsh, James W.

AU - Hong, David

PY - 2017/1/1

Y1 - 2017/1/1

UR - http://www.scopus.com/inward/record.url?scp=85010213493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010213493&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-2621

DO - 10.1158/1078-0432.CCR-16-2621

M3 - Letter

C2 - 28049161

AN - SCOPUS:85010213493

SN - 1078-0432

VL - 23

SP - 321

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 1

ER -

Phase I trial: SABR and ipilimumab - Response

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this